Agenus Inc. (NASDAQ:AGEN) Given Average Rating of “Hold” by Analysts

Shares of Agenus Inc. (NASDAQ:AGEN) have received a consensus rating of “Hold” from the six brokerages that are covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $14.00.

Several equities analysts have commented on the stock. Wall Street Zen raised shares of Agenus from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 22nd. HC Wainwright upgraded Agenus from a “neutral” rating to a “buy” rating and set a $25.00 price target on the stock in a report on Wednesday, June 4th. B. Riley reissued a “buy” rating on shares of Agenus in a research report on Monday, April 21st. Finally, Robert W. Baird upped their price objective on Agenus from $4.00 to $6.00 and gave the company a “neutral” rating in a research note on Wednesday, June 4th.

Agenus Trading Up 7.6%

Shares of NASDAQ:AGEN opened at $5.93 on Friday. The stock has a market cap of $162.60 million, a PE ratio of -0.68 and a beta of 1.51. The stock’s fifty day simple moving average is $4.12 and its two-hundred day simple moving average is $3.18. Agenus has a 1-year low of $1.38 and a 1-year high of $18.74.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.61) by $0.58. The firm had revenue of $24.07 million for the quarter, compared to the consensus estimate of $26.38 million. On average, sell-side analysts forecast that Agenus will post -12.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Agenus

Several institutional investors and hedge funds have recently bought and sold shares of AGEN. Corton Capital Inc. bought a new stake in shares of Agenus in the fourth quarter valued at $36,000. Virtu Financial LLC purchased a new stake in Agenus in the 4th quarter worth about $51,000. Apollon Wealth Management LLC increased its holdings in Agenus by 25.0% in the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 5,000 shares during the last quarter. Bank of Montreal Can bought a new stake in Agenus in the 4th quarter valued at about $69,000. Finally, Barclays PLC lifted its holdings in Agenus by 17.7% during the fourth quarter. Barclays PLC now owns 32,737 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 4,924 shares during the last quarter. 61.46% of the stock is owned by institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.